Compare Becton Dickinson and Co (BDX) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs KLA Corp. — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while KLA Corp. trades at $235.02 (market cap $300.93B). The key difference: KLA Corp. is far larger — about 7.2× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | KLAC | |
|---|---|---|
Market Cap | $41.51B | $300.93B |
Sector | Health | Technology |
52-Week High | $185.39 | $301.71 |
52-Week Low | $135.49 | $84.39 |
Enterprise Value | $57.97B | $302.11B |
Dividend Yield | 2.79% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
KLA Corporation (KLAC) trades at $222.25, down 4.0% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock exhibits strong fundamentals with revenue growth to $12.16B in 2025 and net income of $4.06B, though valuation multiples remain elevated. Recent corporate actions include a 1:10 stock split effective June 12, 2026, and a $2.30 dividend paid in June 2026.
Outlook remains supported by AI-driven semiconductor equipment demand and consistent earnings beats, but rich valuation and competitive pressures pose risks. Analyst consensus is bullish with a $239.86 price target, suggesting potential upside from current levels if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
